Role of Natural Bioactive Compounds in the Rise and Fall of Cancers

Volume 2

Edited by
October 2020
318 pages
  • ISBN978-3-03943-292-9 (Hardback)
  • ISBN978-3-03943-293-6 (PDF)

This book is a reprint of the Special Issue Role of Natural Bioactive Compounds in the Rise and Fall of Cancers that was published in

Biology & Life Sciences
Medicine & Pharmacology
Recent years have seen the idea of a close association between nutrition and the modulation of cancer development/progression reinforced. An increasing amount of experimental and epidemiological evidence has been produced supporting the concept that many different bioactive components of food (e.g. polyphenols, mono- and polyunsaturated fatty acids, methyl-group donors, etc.) may be implicated in either the promotion of or the protection against carcinogenesis. At the cellular level, such compounds can have an impact on different but sometimes intertwined processes, such as growth and differentiation, DNA repair, programmed cell death, and oxidative stress. In addition, compelling evidence is starting to build up of the existence of primary epigenetic targets of dietary compounds, such as oncogenic/oncosuppressor miRNAs or DNA-modifying enzymes, which in turn impair gene expression and function. Since there is a growing interest in the study of the biochemical and molecular role played by food components and its impact on cellular processes and/or gene expressions directed towards the fine-tuning of cancer phenotypes, in this Special Issue researchers contributed with either research or review articles presenting the latest findings on the intracellular pathways and mechanisms affected by natural bioactive dietary molecules.
  • Hardback
License and Copyright
© 2020 by the authors; CC BY-NC-ND license
berberine; signaling pathways; oncogenic cascades; TRAIL; microRNAs; cancer therapy; colon cancer cells; ethanol; Nrf2; HO-1; ER stress; autophagy; MMPs; formononetin; cancer; preclinical models; cell signaling; angiogenesis; nobiletin; colorectal cancer; chemoprevention; bioactivities; experimental therapeutics; HDAC; multiple myeloma; oleacein; breast cancer; persistent organic pollutants; breast cancer risk; breast cancer prognostic; systematic review; carrageenan; invasion; metastasis; RacGAP1; radiotherapy; marine sponge; natural product; anticancer drug; oral cancer inhibition; phytochemicals; small organic agents; Piper eriopodon, alkenylphenols; human cancer cells; cell death; apoptosis; caspase-independent cell death; XIAP antagonists; XIAP-BIR3 domain; Calocedrus formosana; lung cancer; yatein; cell-cycle arrest; xenograft; isorhamnetin; G2/M arrest; apoptosis; ROS; AMPK; pancreatic cancer; epigallocatechin-3-gallate (EGCG); gemcitabine; glycolysis; ROS; phosphofructokinase; lung cancer; natural polyphenols; anticancer activities; molecular mechanisms; Streptomyces; mangrove; anti-proliferative; apoptosis; colon cancer; epithelial mesenchymal transition; inflammation; malignant cancer; natural anti-inflammatory compounds; pro-resolving lipids; anticancer drugs; flavonoids; natural compounds; Xenopus laevis; AOM/DSS model; melanoma cells; nicotine; α9-nAChR; PD-L1; STAT3; gigantol; AKT; JAK/STAT; cancer stem cell; tumor maintenance; tumor density; lung cancer; proteomics; honokiol; anticancer; mechanism; signalling pathway; uterine sarcoma; gemcitabine; fucoidan; isobolography; colchicine alkaloid; colon cancer cells; mesoporous silica nanoparticles; targeted delivery system; apoptosis; PD-1 immune checkpoint inhibitor and cancer immunotherapy; breast cancer; glucose transport; drugs; natural compounds; innate immunity; β-glucans; nutrition; immunotherapy; cancer; estrogen; estrogen receptor alpha; polyphenols; daidzein; daidzein metabolites; paclitaxel; apoptosis; breast cancer cells; obesity; breast cancer; renin–angiotensin system; eicosapentaenoic acid; adipocyte inflammation; olive leaf extract; oleuropein; Seahorse analysis; cancer metabolism; glycolytic markers; Malva pseudolavatera Webb & Berthel.; apoptosis; acute myeloid leukemia; reactive oxygen species; brain cancer; gliomas; schwannomas; malignant tumors of the peripheral nerve sheath (MPNST); neurofibromas; polyphenols; bioavailability; nanoparticle-based delivery systems; natural bioactive compound; gallic acid; EGFR signaling; p53; PD-L1; immunotherapy; EGCG; signaling pathways; non-coding RNAs; anti-cancer drug; NSCLC; EGFR TKI; FASN inhibitors; resistance; STAT3; EGCG; n/a